Cancer Research

Papers
(The H4-Index of Cancer Research is 67. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Cancer Research in the Age of Big Data867
Abstract 6922: MDM2 inhibitor alrizomadlin induces ferroptosis through p53 dependent and independent pathways in TP53 wildtype NSCLC246
Abstract P84: Sorted cell populations with epigenetically silenced chromosomally dispersed reporter fluorophore gene as a test-system for the screening of non-genotoxic carcinogens186
Abstract IA002: Full circle: Return of value to ovarian cancer research participants, advocates, and survivors175
Abstract IA025: AI-powered discovery of biomarkers from histopathological images in ovarian cancer160
Abstract B058: VEGF inhibition enhances immune checkpoint blockade efficacy in ovarian cancer150
Abstract PR004: Phase 2 study of the PD-L1 inhibitor durvalumab and VEGFR inhibitor cediranib combination with and without PARP inhibitor olaparib in patients with recurrent ovarian cancer144
Abstract A051: Targeting notch signaling pathway with auranofin for endometrial cancer therapy133
Abstract A029: PARP-targeted alpha therapy for the treatment of PARP inhibitor resistant ovarian cancer130
Abstract B039: Application of unsupervised clustering to whole slide images of high-grade serous ovarian cancer predicts prognosis129
The Approaching Darwinian Era in Oncology126
Abstract P51: MCL-1 safeguards activated hair follicle stem cells to enable adult hair regeneration124
Abstract P30: Targeting B7-H3 Positive Solid Tumor Malignancies with Chimeric Antigen Receptor Epstein-Barr Virus Specific T Cells Armoured with An Engineered SerpinB9 Molecule for Improved Persistenc123
Abstract P56: Suppression of Breast Cancer Growth via Inhibition of c-Myc Expression by RUNX3120
Abstract A050: Truncated PPM1D cooperates with the PI3K pathway to drive Diffuse Midline Gliomas118
Abstract B031: Uncovering genetic and regulatory drivers of tumor-specific splicing in pediatric brain tumors108
Abstract A002-PR011: Precision Diagnosis in High-Risk Pediatric Oncology through Integrated Whole Genome, Transcriptome, and Epigenome Profiling107
Abstract 4286: CHK1 as a novel therapeutic target for pleural mesothelioma106
Abstract 3358: Tertiary lymphoid structures (TLS) estimated by AI tools from digital H&E slides significantly enhance survival prediction in high-risk AJCC stages III/IV melanoma106
Abstract A027: Combined AKT and XPO1 Inhibition to Target Chimeric Transcription-Factor Driven Pediatric Sarcoma Pathogenesis105
Abstract A021: CLK inhibition induces mis-splicing of SOX8 in alveolar rhabdomyosarcoma101
Abstract IA003: Intersecting Developmental and Oncogenic Networks in ZFTA Fusion-Driven Brain Cancer99
Abstract 2651: Nuclear prothymosin α suppresses TGF-β-induced EMT by stabilizing smad7: implications for lung cancer progression and metastasis99
Abstract IA005: Fetal barriers to fusion protein-driven leukemogenesis99
Abstract 1701: Investigating trastuzumab-deruxtecan (DS-8201) resistance mechanisms using clinically relevant PDX models and combination strategies with anti-PD-1 antibody98
Abstract A068: A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer97
Abstract A117: Co-priming sonic hedgehog inhibitor sonidegib with plerixafor induces tumor microenvironment transformation that enhances fluorescent nanoparticle deposition in pancreatic tumor xenogra96
Abstract A035: KMT2D Loss Induces Enrichment of Plod2+ Fibroblasts in Pancreatic Cancer94
Neuroblastoma Differentiation: The Untapped Potential of Mitochondrial Uncouplers94
Abstract A027: HuR drives immune evasion, metastases and KRAS addiction in pancreatic ductal adenocarcinoma: implications for IO-based and KRAS inhibitor therapies94
Abstract 524: An integrative approach to unveiling biomarkers and therapeutic targets identifies novel treatment strategy for advanced prostate cancer93
Abstract 515: Repurposing nebivolol with dasatinib and CPI-613: A synergistic strategy to combat triple-negative breast cancer91
Abstract 115: S-adenosyl-methionine (SAM) synthesis protects ovarian cancer from chemotherapy induced DNA damage and contributes to cancer stem cell enrichment90
Abstract 691: Decentralized pan-cancer tumor profiling: a comprehensive performance evaluation of the MSK-IMPACT® Assay with SOPHiA DDMTM90
Abstract 817: A prospective, multi-center, phase IV study to evaluate safety and efficacy of Dr. Reddy’s bevacizumab (DRL_BZ) in patients with solid tumors90
Abstract 365: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma89
Abstract 1108: Tissue and circulating DNA methylation profiling can recapitulate SCLC heterogeneity to enable identification of new biomarkers of clinical relevance89
Abstract 244: Identification of proteins in the oncogenic FLT3-ITD signaling pathway using the APEX2 system89
Abstract 1066: OncoKBTM, MSK’s precision oncology knowledge base: 2024 updates87
Abstract 6063: ROSE12, a novel anti-CTLA-4 Switch antibody™ with FcγR affinity-enhanced Fc, evokes tumor-selective anti-tumor immune activation by extracellular ATP without systemic immune activation85
Abstract 1520: Obesity delays melanoma resistance to BRAF/MEKi inhibitors and alters melanoma metabolism85
Abstract 6096: Acquired CAR-T therapy resistance in a pre-clinical model of pediatric rhabdomyosarcoma minimal residual disease84
Abstract 5726: QLS1103, A highly potent and selective PARP7 inhibitor treating advanced solid tumors84
Abstract 6095: T-PureTM: A bispecific antibody cocktail for T cell isolation from human blood, enabling simple and affordable point-of-care CAR-T manufacturing84
Abstract 5166: Increasing translatability of syngeneic mouse models of cancer through the application of human-validated, clinically relevant gene expression-based measurements of the tumor immune mic82
Abstract 4822: Efficacy of 4-1BB-costimulated NKG2D CAR-T cells for synovial sarcoma in comparison with CAR-T cells targeting other antigens82
Abstract 7205: Targeting diverse pathways for the treatment of KRAS driven non-small cell lung cancer79
Abstract 7326: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases79
Abstract 7446: Stratification of cell therapies in solid tumor organoids using deep learning-derived imaging metrics78
Abstract 7180: DNA methylation profiling of peripheral blood mononuclear cells from small-cell lung cancer patients treated with hypomethylating agent plus carboplatin78
Abstract 7388: Trends of diagnosis disclosure among individuals with plasma cell disorders76
Abstract 7374: Body size and composition in relation to PI3K/AKT/mTOR signaling: insights into cancer risk and outcomes - a systematic review75
Abstract 4454: Cancer cell permeability induced by tumor treating fields (TTFields) improves chemotherapy uptake and requires cells to transverse through the G2/M phase under TTFields application73
Abstract 6271: Interactions between CD8+ T cells and tumor cells decode tumor heterogeneity and provide treatment recommendations for colorectal cancer73
Abstract 7211: Proteolysis targeting chimeras (PROTACs) of oncogenic RET protein73
Abstract 5365: Comparison of whole genome sequencing and target capture sequencing in lung cancer73
Abstract 7131: Integrative single-cell transcriptomic and epigenomic immune profiling reveals parallel insights into cancer research73
Abstract 4575: mRNA expression in paired saliva and blood samples from different cancer indices73
Abstract 140: Profiling ECM biomarkers PRO-C3 and PRO-C5 in plasma from patients with esophagogastric cancer71
Abstract 3434: Evaluation of TCR-engineered T cells specific for KRAS G12V mutant peptide presented by HLA-A*02:0171
Abstract 2119: Targeting KIT in chromophobe renal cell carcinoma70
Abstract 1348: Investigation of sex disparity in hepatocarcinogenesis using a hydrodynamic tail vein injection mouse model69
Abstract 88: Ephrin receptor A4 is a regulator of metastatic colonization in triple negative breast cancer69
Abstract 2804: Long non-coding RNA LINC01614 regulates ferroptosis-mediated carcinogenic phenotypes in papillary thyroid cancer68
Abstract 6198: Framework for Pacific Island Cancer and Obesity Across the Lifespan: PICOLI, A multi-dataset analysis approach68
Abstract 3915: An orthotopic model for murine urothelial carcinoma with response to standard of care checkpoint inhibitor treatment67
Abstract 2056: Development of a response prediction Model for venetoclax-based therapy utilizing molecular interactions among BCL2 family members67
0.22021198272705